MedTrace Logo

A Phase I Study to Evaluate LIFE-001

NCT06904807 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-03-19

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if LIFE-001 is safe and tolerable for healthy adult volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

LIFE-001

Single dose of LIFE-001 between 10mg and 750mg administered subcutaneously

DRUG

Placebo

Single dose of placebo comparator administered subcutaneously

DRUG

LIFE-001 MAD

Four doses of LIFE-001 between 50mg and 750mg administered subcutaneously seven days apart

DRUG

Placebo MAD

Four doses of placebo comparator administered subcutaneously seven days apart

Sponsors & Collaborators

  • LifeMine Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephen Hall · Veritus Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-07
Primary Completion
2026-11-13
Completion
2026-11-13

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06904807 on ClinicalTrials.gov